Search company, investor...

IRX Therapeutics

Founded Year



Acquired | Acquired

Total Raised


About IRX Therapeutics

IRX Therapeutics develops immune therapies to treat cancer and related diseases. The company's therapies are designed to target and restore the immune system in order to improve a patient's response to next-generation cancer vaccines and targeted therapeutics. The Company's product platform under development seeks to restore the immune system of cancer patients, which is suppressed by the onset of the disease.

Headquarters Location

654 Madison Avenue Suite 1601

New York, New York, 10065,

United States


Missing: IRX Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: IRX Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing IRX Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

IRX Therapeutics is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

IRX Therapeutics Patents

IRX Therapeutics has filed 16 patents.

patents chart

Application Date

Grant Date


Related Topics




Infectious causes of cancer, Papillomavirus, Gynaecological cancer, Vaccines, Immunology


Application Date


Grant Date



Related Topics

Infectious causes of cancer, Papillomavirus, Gynaecological cancer, Vaccines, Immunology



Latest IRX Therapeutics News

IRX Therapeutics acquired by Brooklyn ImmunoTherapeutics

Nov 8, 2018

IRX Therapeutics acquired by Brooklyn ImmunoTherapeutics X US-based Brooklyn ImmunoTherapeutics, a newly formed company, has acquired the assets of IRX Therapeutics for an undisclosed price. Photo: courtesy of rawpixel/ Subscribe to our email newsletter This name reflects the company’s focus on advancing the science of cytokine-based immunotherapy for the treatment of a range of cancers. Brooklyn ImmunoTherapeutics general partner and board chair Charles Cherington said: “Cytokine-based immunotherapy overcomes immune suppression to activate an immune attack on tumors by upregulating multiple checkpoints and represents an exciting new approach to treating cancer. “In a Phase 2A clinical trial, IRX-2, our clinical drug candidate, demonstrated an improvement in progression free survival and overall survival in patients with head and neck squamous cell carcinoma. We believe this unique injectable cytokine mixture amplified from normal donor lymphocytes has the potential to improve patient outcomes both as a single agent and in combination with other anti-cancer agents. “We are committed to exploring this potential in a range of solid tumors including breast cancer, cervical and vulvar neoplasms, renal cell carcinoma, hepatocellular carcinoma, gastric and esophageal cancer as well as other solid tumor indications.” A global, multicenter, randomized, double-blind, placebo-controlled Phase 2B clinical trial of IRX-2 (INSPIRE trial, NCT02609386) in 105 patients with head and neck squamous cell carcinoma has completed enrollment with results expected in mid-2020 (CIN: NCT03267680, Breast: NCT02950259). About IRX-2 IRX-2 is a proprietary therapeutic containing numerous active cytokine components, which data suggests may restore and activate multiple immune cell types, including T cells, dendritic cells and natural killer cells, which are known to recognize and attack tumors. IRX-2 is a primary cell-derived biologic produced by stimulation of human peripheral blood mononuclear cells (PBMCs) obtained from healthy donor whole blood. Data collected to date suggest that IRX-2 reduces the immune suppression that is often seen in the cancer tumor microenvironment. This immunomodulatory activity appears to occur through the restoration of immune function and activation of a coordinated immune response against the tumor. Source: Company Press Release

IRX Therapeutics Frequently Asked Questions (FAQ)

  • When was IRX Therapeutics founded?

    IRX Therapeutics was founded in 1994.

  • Where is IRX Therapeutics's headquarters?

    IRX Therapeutics's headquarters is located at 654 Madison Avenue, New York.

  • What is IRX Therapeutics's latest funding round?

    IRX Therapeutics's latest funding round is Acquired.

  • How much did IRX Therapeutics raise?

    IRX Therapeutics raised a total of $153.21M.

  • Who are the investors of IRX Therapeutics?

    Investors of IRX Therapeutics include Brooklyn ImmunoTherapeutics, Amberjack Capital Partners, Halpern Denny and Co., Lilly Ventures, MP Healthcare Venture Management and 7 more.

  • Who are IRX Therapeutics's competitors?

    Competitors of IRX Therapeutics include ViaCyte, DiscoveryBioMed, Cognition Therapeutics, Five Prime Therapeutics, BioNano Genomics and 11 more.

Compare IRX Therapeutics to Competitors

Welichem Biotech

Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.

IITRI Drug Discovery Division

IIT Research Institute (IITRI) is a contract research organization (CRO) that aims to provide non-clinical toxicology and other drug development services to government and industry. IITRI offers particular expertise in oncologics drug development, inhalation toxicology and technology, carcinogenesis and cancer prevention, and biodefense. IITRI's Drug Discovery Division is a research-based group whose focus is the design and synthesis of new small molecule therapeutics for cancer and infectious disease.

Molecular LogiX

Molecular LogiX (MLX) is a drug discovery company located in The Woodlands, Texas, that seeks to discover therapeutics through the application of rationale protein engineering technologies. The company is currently developing protein-based drugs to treat cancer by interfering with established tumor growth factor pathways.

Echelon Biosciences Logo
Echelon Biosciences

Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brain development, immunological competence and the regulation of blood pressure. Both LPA and autotaxin have also been implicated in numerous diseases, especially metastatic cancer. Autotaxin was identified as one of the 40 most induced genes in aggressive breast cancer. The broader impacts of this research are the discovery and commercialization of tools that easily highlight specific biological pathways in living organisms. ATXRed will be welcomed by basic researchers in many fields associated with autotaxin and LPA. However, the utility extends beyond the basic research sphere. ATXRed smart probes could also aid pharmaceutical researchers searching for pharmacological inhibitors of autotaxin and LPA receptor agonists and antagonists. ATXRed would be a powerful tool in many rodent models of human cancer. In vivo autotaxin imaging probes could also aid in the clinic by helping to identify and monitor disease progression and treatment. Ultimately, ATXRed could help guide surgical resection of tumorstumors previously identified by the smart probe to have elevated autotaxin activity. In total, ATXRed probes have the potential to impact basic research, drug discovery and the clinic as a prime example of molecular medicine applied from bench to bedside.

We Are Cellix Logo
We Are Cellix

We Are Cellix provides microfluidic solutions and inish solutions for cell analysis and sorting. It offers products such as inish analyzers, biochips, microfluidic pumps, and more. It was founded in 2006 and is based in Dublin 12, Ireland.


Amura is a structure-based drug discovery business specialising in diseases such as osteoporosis, bone metastasis, autoimmunity, chronic pain and malaria. Amura has a scaffold (AMcore) that aims to provide a turnkey solution for the discovery of small-molecule inhibitors against cysteine peptidases (e.g. cathepsin enzymes); which are commercially attractive therapeutic targets

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.